Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1 - 125 (canceled)

- 126. (New) An isolated polypeptide selected from the group consisting of:
 - (a) a polypeptide comprising an amino acid sequence of SEQ ID NO: 1;
 - (b) a biologically active fragment of the polypeptide of (a); and
 - (c) an immunogenic fragment of the polypeptide of (a).
- 127. (New) An isolated polypeptide of claim 126 consisting of the polypeptide of (a).
- 128. (New) An isolated polypeptide of claim 126 consisting of a biologically active fragment of the polypeptide of (a).
- 129. (New) An isolated polypeptide of claim 126 consisting of an immunogenic fragment of the polypeptide of (a).
- 130. (New) An isolated polypeptide of claim 126 encoded by a polynucleotide selected from the group consisting of:
 - (i) a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 2;
- (ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to SEQ ID NO: 2;
- (iii) a polynucleotide comprising a portion of the polynucleotide sequence of SEQ ID NO: 2 that specifically identifies SEQ ID NO: 2.
- (iv) a polynucleotide comprising a polynucleotide complementary to the polynucleotide of (i), (ii), or (iii);
 - (v) an RNA equivalent of the polynucleotide of (i), (ii), (iii) or (iv);
- (vi) a polynucleotide of (i), (ii) or (iii) further comprising a promoter sequence operably linked to said polynucleotide of (i), (ii) or (iii).
- 131. (New) An isolated polypeptide of claim 126 produced recombinantly.

- 132. (New) An isolated polypeptide of claim 130 produced by culturing a cell transformed with a polynucleotide of (iv) under conditions suitable for expression of the polypeptide, and recovering the polypeptide so expressed.
- 133. (New) An isolated antibody that specifically binds to a polypeptide of claim 126.
- 134. (New) An isolated antibody of claim 133, wherein said antibody is selected from the group consisting of a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a single chain antibody, a Fab fragment, a F(ab')₂ fragment, and a humanized antibody.
- 135. (New) An isolated antibody of claim 134, wherein said antibody is selected by screening a recombinant immunoglobulin library.
- 136. (New) An isolated antibody of claim 134, wherein said antibody is selected by screening a Fab expression library.
- 137. (New) An isolated antibody that specifically binds to a polypeptide of claim 130.
- 138. (New) An isolated antibody of claim 137, wherein said antibody is selected from the group consisting of a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a single chain antibody, a Fab fragment, a F(ab')₂ fragment, and a humanized antibody.
- 139. (New) An isolated antibody of claim 137, wherein said antibody is selected by screening a recombinant immunoglobulin library.
- 140. (New) An isolated antibody of claim 137, wherein said antibody is selected by screening a Fab expression library.
- 141. (New) A method of detecting a polypeptide of interest in a sample, comprising: incubating the sample with an antibody that specifically binds to a polypeptide of claim 126 under conditions suitable for binding of the antibody to the polypeptide of interest if present in the sample; and

detecting biding of the polypeptide of interest to the antibody, wherein binding indicates the presence or amount of the polypeptide of interest in the sample.

- 142. (New) A method of claim 141, wherein the sample is a body fluid sample from a human.
- 143. (New) An isolated polynucleotide selected from the group consisting of:
 - (i) a polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 2;
- (ii) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to SEQ ID NO: 2;
- (iii) a polynucleotide comprising a portion of the polynucleotide sequence of SEQ ID NO: 2 that specifically identifies SEQ ID NO: 2.
- (iv) a polynucleotide comprising a polynucleotide complementary to the polynucleotide of (i), (ii), or (iii);
 - (v) an RNA equivalent of the polynucleotide of (i), (ii), (iii) or (iv);
- (vi) a polynucleotide of (i), (ii) or (iii) further comprising a promoter sequence operably linked to said polynucleotide of (i), (ii) or (iii).